Evidence map›Paper›PMID 22593761›Full record

ArticleFrontiers in immunology2012

The Fyn-STAT5 Pathway: A New Frontier in IgE- and IgG-Mediated Mast Cell Signaling.

Nicholas A Pullen, Yves T Falanga, Johanna K Morales, John J Ryan

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 34 citations in OpenAlex.

  1. International journal of nanomedicine · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. JAK inhibitors for asthma.The Journal of allergy and clinical immunology · 2021
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Evidence-based complementary and alternative medicine : eCAM · 2019
    Article
  12. Article
  13. Review
  14. The Expression ofTanaffos · 2017
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Nicholas A PullenDepartment of Biology, The Asthma and Allergic Disease Cooperative Research Center, Virginia Commonwealth University Richmond, VA, USA.
Yves T Falanga
Johanna K Morales
John J Ryan
Virginia Commonwealth University · US

Funding

Virginia Commonwealth University IRADCAK12GM093857 · NIGMS · VIRGINIA COMMONWEALTH UNIVERSITY · PI DANIEL C BULLARD, John J Ryan · 2010 to 2026
$7.0M
NIGMS NIH HHS K12 GM093857
6 · The paper itself

Abstract

Mast cells are central players in immune surveillance and activation, positioned at the host-environment interface. Understanding the signaling events controlling mast cell function, especially those that maintain host homeostasis, is an important and still less understood area of mast cell-mediated disease. With respect to allergic disease, it is well established that IgE and its high affinity receptor FcεRI are major mediators of mast cell activation. However, IgG-mediated signals can also modulate mast cell activities. Signals elicited by IgG binding to its cognate receptors (FcγR) are the basis for autoimmune disorders such as lupus and rheumatoid arthritis. Using knowledge of IgE-mediated mast cell signaling, recent work has begun to illuminate potential overlap between FcεRI and FcγR signal transduction. Herein we review the importance of Src family kinases in FcεRI and FcγR signaling, the role of the transcription factor STAT5, and impingement of the regulatory cytokines IL-4, IL-10, and TGFβ1 upon this network.

Indexed as

FynIgEIgGIL-10IL-4mast cellStat5TGF

Identifiers

PMID22593761
PMCPMC3350083
OpenAlexW2098157541

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.